Pediatric MS & Demyelinating Disorders
Acquired demyelinating syndromes (ADS) in children are acute neurologic illnesses characterized by deficits persisting ≥24 hours involving the optic nerves, brain, or spinal cord, with associated regional T2 signal abnormalities on MRI. While many episodes are monophasic, approximately 20% of children will experience further episodes, with the risk dependent on the specific clinical syndrome, antibody status, and MRI features at presentation. The spectrum encompasses pediatric multiple sclerosis (MS), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and several rarer autoimmune and autoinflammatory conditions. Accurate early classification is essential because these conditions differ fundamentally in pathophysiology, treatment, and prognosis.
Bottom Line
- ADS presentations: Monofocal optic neuritis, monofocal inflammatory myelitis, polyfocal deficits with encephalopathy (ADEM), and polyfocal deficits without encephalopathy — each carrying different relapse risk profiles
- Essential workup for ALL ADS: Brain and spine MRI with contrast, CSF with oligoclonal bands, serum MOG-IgG and AQP4-IgG antibodies
- Pediatric MS: Higher relapse rate and more rapid MRI lesion accrual than adult MS; predominantly relapsing-remitting; favor early use of highly effective disease-modifying therapies (DMTs)
- Pediatric AQP4+ NMOSD: Rare (<5% of pediatric ADS) but severe; stepwise attack-related disability accrual; initiate relapse prevention at diagnosis
- Pediatric MOGAD: Most common antibody-mediated pediatric ADS; two-thirds monophasic; age-dependent phenotypes (ADEM in younger children, ON/myelitis in adolescents); maintenance therapy NOT recommended after first attack
- Nearly half of children with relapsing demyelinating syndromes have non-MS phenotypes — test MOG-IgG and AQP4-IgG in all patients; negative antibodies with atypical features should prompt investigation for monogenic disorders
Acquired Demyelinating Syndromes: Overview
ADS represent the initial clinical presentation of CNS demyelination in children and can be classified by their anatomical pattern and presence or absence of encephalopathy. This initial classification helps guide the diagnostic workup and provides an early estimate of the likelihood of chronic disease.
| Presentation Pattern | Description | Key Associations |
|---|---|---|
| Monofocal optic neuritis | Isolated optic nerve involvement with visual loss | MOGAD (especially bilateral), MS, AQP4+ NMOSD |
| Monofocal inflammatory myelitis | Isolated spinal cord involvement | All three antibody-mediated disorders; LETM favors MOGAD/NMOSD |
| Polyfocal with encephalopathy (ADEM) | Multifocal deficits with altered consciousness | MOGAD (>50% of ADEM), monophasic post-infectious |
| Polyfocal without encephalopathy | Multifocal deficits with preserved consciousness | MS (highest risk of chronic relapsing disease) |
When a child presents with relapsing demyelination but does not have a confirmed diagnosis (antibody-negative, does not meet MS criteria), investigation should extend beyond inflammatory etiologies to include noninflammatory mimics such as genetic leukoencephalopathies, mitochondrial disorders, and autoinflammatory syndromes (e.g., CNS hemophagocytic lymphohistiocytosis).
Management of Acute Demyelinating Attacks
Acute Treatment Protocol
- First-line: IV methylprednisolone 30 mg/kg/day (maximum 1 g/day) for 3–5 days, typically followed by a 4–6 week oral prednisolone wean
- Steroid non-responders or severe attacks (complete vision loss, paralysis, extreme encephalopathy requiring ICU): Escalate to plasma exchange (PLEX, 5 cycles) and/or IV immunoglobulin (IVIg, 2 g/kg over 2–5 days)
- PLEX vs. IVIg: PLEX is generally considered superior to IVIg for acute management; if both are needed, PLEX should be performed first (PLEX removes IVIg from the circulation)
- Tocilizumab (IL-6 receptor inhibitor): Has been used successfully for fulminant MOGAD not responsive to steroids and PLEX
- Steroid wean monitoring: During 4–6 week prednisolone taper, monitor blood pressure, urine glucose, and early morning cortisol before discontinuation
- Steroid-sparing agents: Consider if repeated relapses require multiple steroid courses, given chronic corticosteroid adverse effects in children
Clinical Presentations of ADS
| Presenting Phenotype | Presentation | MRI | Key Investigations | Treatment | Outcome |
|---|---|---|---|---|---|
| ADEM | Polyfocal neurologic deficits with encephalopathy (altered consciousness, behavioral change); typically ages 3–7; often preceded by viral infection or vaccination; seizures in up to 30% | Large, bilateral, ill-defined T2/FLAIR white matter lesions; deep grey matter involvement (thalami, basal ganglia) common; may involve brainstem and spinal cord; lesions do NOT follow MS distribution patterns | MOG-IgG positive in >50%; AQP4-IgG (rare); CSF pleocytosis common; OCBs usually absent; exclude CNS infection | IV methylprednisolone → oral prednisolone wean (4–6 weeks); IVIg or PLEX for refractory cases; maintenance therapy NOT indicated for first episode even if MOG-IgG positive | Majority recover well; monophasic in most; MOG-IgG positivity may indicate risk of relapse (multiphasic ADEM or transition to ON/myelitis phenotype); 10% with severe phenotype develop cognitive or motor deficits |
| Optic Neuritis | Acute visual loss with pain on eye movement; may be unilateral or bilateral; bilateral simultaneous ON strongly suggests MOGAD; posterior ON with less pain suggests AQP4+ NMOSD | Optic nerve T2 hyperintensity and enhancement; longitudinally extensive (>50% nerve length) with perineural sheath enhancement favors MOGAD; posterior/chiasmal involvement favors AQP4+ NMOSD; short, anterior lesion favors MS | MOG-IgG and AQP4-IgG; brain MRI (dissemination in space for MS); OCBs; visual evoked potentials; OCT for RNFL thickness | IV methylprednisolone → oral wean; PLEX if severe or steroid-refractory; disease-specific maintenance therapy based on antibody status and relapse risk | MOGAD: generally good visual recovery; MS: good early recovery but cumulative risk with relapses; AQP4+ NMOSD: high risk of poor visual recovery and blindness; recurrent ON → cumulative visual loss regardless of etiology |
| Inflammatory Myelitis | Acute motor, sensory, and/or autonomic dysfunction; may present as paraplegia, urinary retention, sensory level; conus involvement (bladder, bowel) favors MOGAD | LETM (≥3 vertebral segments) favors MOGAD or AQP4+ NMOSD; central cord H-sign and conus lesions favor MOGAD; bright spotty lesions favor AQP4+ NMOSD; short, peripheral, dorsal lesions favor MS | MOG-IgG and AQP4-IgG; brain MRI; CSF analysis with OCBs; exclude compressive and vascular myelopathies | IV methylprednisolone → oral wean; PLEX for severe or refractory cases (paralysis); urgent escalation for complete paraplegia or respiratory compromise | MOGAD: generally good motor recovery; lesions often resolve on follow-up MRI; AQP4+ NMOSD: incomplete recovery common, stepwise disability; MS: variable recovery; residual sensory or bladder symptoms common across all etiologies |
Pediatric Multiple Sclerosis
Epidemiology and Etiology
Pediatric MS is predominantly a disease of adolescents, though cases have been reported in children as young as 2 years. Many early reports of prepubertal MS in the literature are now recognized to have been relapsing MOGAD rather than true MS. The etiology involves a complex interplay of environmental and genetic factors, with vitamin D deficiency and Epstein-Barr virus (EBV) infection identified as particularly important contributors.
Diagnostic Pitfall in Young Children
- Many prepubertal cases previously diagnosed as MS are now recognized as relapsing MOGAD
- Nearly half of children with relapsing demyelinating syndromes have non-MS phenotypes
- MOG-IgG and AQP4-IgG testing is essential in ALL pediatric demyelinating presentations
- Atypical presentations with negative antibodies should prompt investigation for monogenic disorders: CNS hemophagocytic lymphohistiocytosis (HLH), leukodystrophies, mitochondrial disease
Diagnosis
The revised 2017 McDonald criteria are applicable to pediatric MS, requiring demonstration of dissemination in space (DIS) and dissemination in time (DIT). Diagnosis can be made at first presentation when radiologic evidence of both DIS and DIT is present (lesions of different ages on initial MRI). Oligoclonal band (OCB) positivity can substitute for DIT.
Diagnostic Criteria — 2017 McDonald Criteria in Children
- Dissemination in space (DIS): ≥1 T2 lesion in ≥2 of 4 locations: periventricular, cortical/juxtacortical, infratentorial, spinal cord
- Dissemination in time (DIT): Simultaneous gadolinium-enhancing and non-enhancing lesions, OR new T2/enhancing lesion on follow-up MRI, OR CSF-specific OCBs (substitutes for DIT)
- MRI at presentation: 94% have periventricular lesions, 74% infratentorial, 73% cortical/subcortical, 59% spinal cord lesions
- Highly inflammatory early disease: Higher lesion load than adult MS at onset; most children fulfill criteria at first presentation
- Phenotype: Almost exclusively relapsing-remitting; primary progressive MS is extremely rare in children
Disease Characteristics
- Higher relapse rate compared to adults, with rapid MRI lesion accrual in the early disease course
- More inflammatory disease with higher lesion load at onset, particularly in younger patients
- Greater long-term risk of cognitive impairment and physical disability
- Treatment effect on brain atrophy correlates with cognitive outcomes — undertreated disease leads to progressive brain volume loss
- Almost exclusively relapsing-remitting phenotype; primary progressive MS is exceedingly rare in children
Treatment: Disease-Modifying Therapies
Treatment Principles in Pediatric MS
- Treat as highly active disease: Favor EARLY initiation of highly effective DMTs (e.g., anti-CD20 monoclonal antibodies such as rituximab)
- Rationale for aggressive treatment: Disease activity drives brain atrophy, cognitive impairment, and earlier transition to secondary progressive MS
- Monitoring: Brain MRI every 6 months recommended; escalate treatment with any evidence of radiologic disease activity
- Off-label prescribing: Most DMTs are prescribed off-label in children; treatment decisions heavily influenced by adult protocols and clinical experience
- Fingolimod: The only FDA-approved oral DMT for pediatric MS (ages ≥10), based on the PARADIGMS trial demonstrating superiority over interferon beta-1a
Long-Term Treatment Considerations
- Duration of therapy: Children may require highly effective DMTs for decades, raising concerns about cumulative toxicity
- Malignancy risk: Prolonged immunosuppression may increase lifetime cancer risk
- Hypogammaglobulinemia: Chronic B-cell depletion (e.g., rituximab) can lead to reduced IgG levels and increased infection susceptibility
- Balancing risks: Undertreated disease results in brain atrophy, motor disability, and cognitive impairment — the consequences of undertreatment must be weighed against treatment toxicity
- Compliance: Adherence and treatment tolerability are critical considerations in the pediatric population
Wellness and Supportive Strategies
- Healthy balanced diet
- Vitamin D supplementation (maintain adequate serum levels)
- Regular physical exercise
- Avoidance of smoking and vaping
- Cognitive monitoring and school accommodations as needed
- Psychosocial support for the patient and family
Pediatric AQP4-Antibody Positive NMOSD
Epidemiology and Clinical Features
Pediatric AQP4+ NMOSD is rare, accounting for fewer than 5% of ADS presentations in children. Approximately 5% of all AQP4+ NMOSD cases present before age 18. Despite its rarity, early diagnosis is critical because NMOSD is more severe than MS and requires fundamentally different treatment approaches.
- Clinical features and MRI findings are similar to the adult phenotype
- Children are more likely to have brain lesions and demonstrate more inflammatory disease overall (paralleling pediatric MS)
- Attack types: Optic neuritis, longitudinally extensive transverse myelitis (LETM), area postrema syndrome, brainstem syndrome
- Stepwise attack-related disability accrual — each relapse carries risk of permanent deficit
- Time to first relapse is shorter in children, with higher pretreatment annualized relapse rate (ARR) compared to adults
Management
Relapse Prevention in Pediatric AQP4+ NMOSD
- Initiate relapse prevention at diagnosis — even after the first event, given the high relapse risk and severity of attacks
- Azathioprine: 2.5 mg/kg/day; requires TPMT testing before initiation; monitor CBC and liver function
- Mycophenolate mofetil: 600 mg/m2 twice daily (maximum 2 g/day); effective and generally well-tolerated
- Rituximab: Achieves the lowest annualized relapse rate among maintenance therapies; patients are more likely to relapse if B-cell repopulation occurs → careful monitoring of CD19/CD20 counts to determine infusion intervals
- FDA-approved adult NMOSD therapies (satralizumab, inebilizumab, eculizumab): Limited pediatric data; satralizumab trial was open to ages 12–18 but only 8 pediatric patients were recruited
Prognosis
| Prognostic Feature | Pediatric AQP4+ NMOSD | Pediatric MS (Comparison) |
|---|---|---|
| Disease severity | Active and severe; frequent relapses | Active but generally less severe individual attacks |
| EDSS at 2 years | 2.25 (higher) | 1.28 (lower) |
| Recovery from individual relapses | Children may recover better than adults from individual attacks | Generally good early recovery |
| Time to fixed disability | Longer than adults (children take longer to reach disability milestones) | Earlier cognitive impairment; later motor disability |
| Disability type by age of onset | Children → predominantly visual disabilities; older patients → predominantly motor disabilities | Cognitive and motor disability |
Pediatric MOGAD
Epidemiology and Key Features
MOGAD is pathophysiologically distinct from both MS and AQP4+ NMOSD. MOG antibodies are detected in over 30% of children with an initial demyelination episode and in more than 50% of children with ADEM, making MOGAD the most common antibody-mediated pediatric ADS. A defining feature of pediatric MOGAD is that two-thirds of cases are monophasic, reflecting heightened resilience and tissue repair capacity in children.
Age-Dependent Phenotypes in Pediatric MOGAD
- Children <10 years: ADEM and encephalitis phenotypes predominate — diffuse, bilateral white matter lesions with encephalopathy, often preceded by infection
- Children ≥10 years: Optic neuritis and myelitis phenotypes predominate — more closely resembling adult MOGAD presentations
- Attack severity at nadir: More severe than MS (somnolence, encephalopathy, seizures, bilateral blindness), but most children recover well
- Rare severe attacks: Occasionally severe enough to require mechanical ventilation
Diagnosis
The 2023 International MOGAD Panel criteria require the combination of a core clinical attack type plus clearly positive serum MOG antibodies by cell-based assay (CBA).
| Criterion | Detail |
|---|---|
| Clearly positive MOG-IgG | Fixed CBA titer ≥1:100, OR live CBA clearly positive |
| Low positive MOG-IgG | Can still diagnose MOGAD if AQP4-IgG is negative AND ≥1 supporting clinical/MRI feature is present |
| Supporting features | Bilateral simultaneous ON; LETM; longitudinally extensive optic nerve involvement; conus lesions |
| Essential exclusion | Alternative diagnoses must be excluded |
Pediatric Groups That May Be Missed
- ADEM-like MRI without encephalopathy: Large, bilateral white matter lesions but normal consciousness — may not be recognized as MOGAD if encephalopathy is absent
- Encephalopathy without ADEM-like MRI: Cortical encephalitis, meningoencephalitis, or even normal brain MRI — testing MOG-IgG in all children with unexplained encephalopathy is important
Treatment Approach
MOGAD Treatment Strategy
- Acute treatment: IV corticosteroids are typically very effective; many children demonstrate complete, dramatic recovery after a short IV course followed by oral taper
- After first attack: Maintenance therapy is NOT recommended, even in MOG-IgG positive patients — given the high rate of monophasic disease (two-thirds of cases)
- When to consider maintenance: Severity of previous attack, presence of residual disability, weighing treatment benefits against regression to the mean and side effect risks
- Maintenance options for relapsing MOGAD: IVIg (commonly used; may work through Fc-receptor-mediated mechanism), rituximab, mycophenolate mofetil, azathioprine
- ~10% severe phenotype: Multiple brain relapses leading to cognitive, motor, and visual disabilities — these patients require aggressive long-term immunotherapy
Prognosis and Biomarker Monitoring
- Two-thirds of pediatric MOGAD is monophasic with full or near-full recovery
- MOG antibody titers do NOT clearly correlate with disability outcomes
- Baseline MRI features are not predictive of relapse or disability risk
- MOG antibody seroconversion to negative is associated with lower relapse risk — serial antibody monitoring may help guide treatment duration
- Approximately 10% develop a severe relapsing phenotype with cumulative cognitive, motor, and visual deficits
Rare Autoimmune Conditions in Children
| Condition | Key Features | Typical Age | Pathophysiology | MRI/Investigations | Treatment & Outcome |
|---|---|---|---|---|---|
| Rasmussen Encephalitis | New-onset aggressive epilepsy, often presenting as epilepsia partialis continua (continuous focal motor seizures); progressive unilateral hemispheric dysfunction with hemiparesis, cognitive decline, and visual field loss | 5–15 years | T-cell mediated autoimmune process targeting one cerebral hemisphere; not antibody-mediated | Progressive unilateral hemispheric atrophy; T2/FLAIR signal change expanding over time; contralateral hemisphere spared; EEG shows unilateral epileptiform activity | Immunotherapy (steroids, IVIg, tacrolimus) does NOT prevent progression; antiepileptic drugs often insufficient; functional hemispherectomy may be required for seizure control; results in fixed contralateral hemiparesis and hemianopia |
| CNS Vasculitis (Childhood Primary Angiitis of the CNS) | Headache, focal neurologic deficits, seizures, cognitive decline, stroke-like episodes; may present acutely or with progressive course | Variable (childhood and adolescence) | Inflammatory vasculopathy affecting small and/or large cerebral vessels; may be primary or secondary to systemic vasculitis | Multifocal ischemic lesions; vessel wall enhancement on MRI; conventional angiography may show beading/stenosis of large vessels; brain biopsy may be needed for small-vessel disease; ESR, CRP often elevated | Immunosuppression with corticosteroids ± cyclophosphamide, mycophenolate, or azathioprine; large-vessel disease may respond better to treatment; small-vessel disease requires brain biopsy for definitive diagnosis; prognosis variable |
| MIS-C (Multisystem Inflammatory Syndrome in Children) | Post-infectious hyperinflammatory syndrome following SARS-CoV-2 infection; fever, multiorgan involvement (cardiac, gastrointestinal, mucocutaneous); neurologic involvement in approximately 50% of cases (headache, encephalopathy, seizures, focal deficits) | School-age children and adolescents | Postinfectious immune dysregulation with cytokine storm; not direct viral neurotropism | Characteristic splenial lesion of the corpus callosum on MRI; may have additional white matter or cortical lesions; elevated inflammatory markers (CRP, ferritin, D-dimer, IL-6); cardiac biomarkers (troponin, BNP) | IV methylprednisolone + IVIg + anakinra (IL-1 receptor antagonist) for severe cases; majority of neurologic symptoms resolve with systemic treatment; cardiac involvement may require inotropic support; generally favorable neurologic prognosis with appropriate treatment |
Differential Diagnosis: Pediatric MS vs. MOGAD vs. AQP4+ NMOSD
| Feature | Pediatric MS | Pediatric MOGAD | Pediatric AQP4+ NMOSD |
|---|---|---|---|
| Biomarker | None specific; OCBs positive >85% | MOG-IgG (CBA) | AQP4-IgG (CBA) |
| Age at onset | Predominantly adolescents | Bimodal (<10y: ADEM; ≥10y: ON/myelitis) | Any age; rare overall in children |
| Frequency in pediatric ADS | ~20% of ADS | >30% of initial ADS; >50% of ADEM | <5% of ADS |
| Disease course | Relapsing-remitting (>95%) | ~67% monophasic; ~33% relapsing | >90% relapsing |
| Brain MRI | Periventricular, cortical/juxtacortical, infratentorial, ovoid lesions | Large, bilateral, ill-defined; cortical encephalitis; deep grey matter | Periependymal, area postrema; more brain lesions than adults |
| Spinal cord MRI | Short, peripheral, dorsal lesions | LETM, conus, H-sign; lesions resolve | LETM, central, bright spotty lesions |
| OCBs | Positive >85% | Usually absent (<20%) | Usually absent (<20%) |
| Treatment approach | Early high-efficacy DMTs (anti-CD20) | No maintenance after 1st attack; IVIg if relapsing | Relapse prevention at diagnosis (rituximab, AZA, MMF) |
| Recovery from attacks | Generally good early | Excellent (despite severe nadir) | Variable; better in children than adults |
| Long-term disability | Cognitive + motor; brain atrophy | ~10% develop severe cumulative deficits | Stepwise attack-related; visual predominant |
References
- Hacohen Y. Pediatric autoimmune neurologic disorders. Continuum (Minneap Minn). 2024;30(4):1160-1188.
- Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282.
- Chitnis T, Ghezzi A, Baier M, et al. Fingolimod in pediatric multiple sclerosis (PARADIGMS): a randomised, phase 3 study. Lancet Neurol. 2018;17(7):583-592.